Klik hier om dit forumtopic te volgen en automatisch op de hoogte gehouden te worden bij nieuwe berichten.
today announced that the Company was invited to present an overview of AsiDNA™ for the treatment of solid tumors at the 2nd DNA Damage Response Therapeutics Summit (DDRTS) to be held January 29-31, 2019, in Boston, MA.
Er zal toch vandaag of morgen wat nieuws naar buiten moeten komen.
Financially, we continued to diversify our resources through the monetization of the Beleodaq® royalties for $7.5 million. We also set up a line of equity financing, thereby providing the resources to finance our development plan until the next value drivers expected in 2019.
On the sound foundations of these scientific and operational advances, we approach 2019 with serenity. The year will be marked by several key milestones such as conducting the European study of AsiDNA™ in combination and obtaining its first results as well as filing of an Investigational New Drug (IND) application during the second half of the year to initiate clinical trials in the United States.
We are also in the process of finalizing and optimizing our next innovative drug candidate. It originates from our proprietary PlatON™ platform, however its properties differ from those of AsiDNA™. This program is expected to move into regulatory preclinical testing in the coming weeks, thereby strengthening the company's portfolio by capitalizing on our oligonucleotide expertise.
On behalf of the entire team, I thank you for your support and confidence in our strategy to make Onxeo a leading player in oncology. I wish you happiness and success for 2019.
It is with great pleasure that I write to you at
the start of this new year. Before discussing
Onxeo’s prospects for 2019, I would like to
share with you the major achievements of
the past year, which strongly contributed to
structuring the future of your Company.
In 2018 our teams successfully completed
all the planned development stages of our
first-in-class candidate, AsiDNA™, in the
sought-after field of tumoral DNA damage
Mooie berichten nu de koers nog sky high;)
rationeel schreef op 29 jan 2019 om 19:45:
Mooie berichten nu de koers nog sky high;)
Maar hoe hoog is sky high?
Het mag nog wel flink stijgen wil ik eerst mijn break even point weer halen.
Er zit geen enkele vaart in. Sterker nog, het daalt elke week iets. Komt het nog goed?
Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting
The press release in PDF
Paris (France), February 13, 2019 – 6.00 pm CET - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today announced that results of five preclinical study supporting the differentiated profile of AsiDNA™, its first-in-class DNA Damage Response (DDR) inhibitor, including insights into the compound’s unique mechanism of action, will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held March 29 - April 3, 2019, in Atlanta, GA, USA.
Françoise Bono, PhD, Chief Scientific Officer, commented: “We are thrilled to have had five AsiDNA™-related abstracts accepted for presentation at this prestigious meeting of oncology, including 2 abstracts resulting from our long-standing collaboration with Institut Curie, an internationally recognized research institution. The study to be presented notably support the absence of the emergence of resistance to AsiDNA™ after repeated treatments and the abrogation of acquired resistance to PARP inhibitors when administered in combination with AsiDNA™, two properties that make AsiDNA™ so distinctive and sustain its promising potential for future utilization in clinic. New data also provide valuable insights into the underlying mechanisms supporting these unique outcomes and their potential benefits in oncology. Furthermore, we have identified predictive biomarkers of sensitivity to AsiDNA™, a strong advantage to optimize its clinical development and which could, ultimately, open the way to personalized medicine with AsiDNA™. Lastly, these results expand the solid preclinical package on AsiDNA™, further support the strong rationale for its ongoing development in the clinical setting and confirm its interest and its value in our company portfolio."
Titles of the five abstracts to be presented during poster sessions are:
• AsiDNA™, a targeted therapy with no acquired resistance
• AsiDNA™ abrogates acquired resistance to PARP inhibitors
• Molecular analysis of the mechanism of action of AsiDNA™ brings new clues on DNA damage response regulation
• Development of a biomarker-driven patient selection strategy for AsiDNA™ treatment (in collaboration with Institut Curie)
• AsiDNA™, a novel DNA repair inhibitor to sensitize aggressive medulloblastoma subtypes(Institut Curie)
Details on the date, time and location of the sessions during the congress will be provided when available.
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a French biotechnology company developing innovative oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after mechanisms of action in cancer treatment today. The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
Onxeo is developing AsiDNA™, a first-in-class and highly differentiated tumor DNA Damage Response inhibitor, based on an original decoy and agonist mechanism that acts upstream of multiple DDR pathways. Translational studies have demonstrated unique properties of AsiDNA ™, including an increasing sensitivity of tumor cells to AsiDNA™ after repeated treatment with AsiDNA ™ and the ability to stop and even reverse the resistance of tumor cells to PARP inhibitors, regardless the genetic mutation status. AsiDNA™ has also shown strong synergy with other tumor DNA damaging agents such as chemotherapies or PARP inhibitors. The ongoing Phase I study DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) evaluates AsiDNA™ by systemic administration (IV) in solid tumors and has recently produced favorable tolerability and activity results.
AsiDNA™ is the first compound generated from platON™, the Company’s proprietary chemistry platform of decoy oligonucleotides. PlatON™ will continue to generate innovative compounds targeting tumor DNA-binding functions and broaden Onxeo’s pipeline.
Onxeo’s R&D pipeline also includes belinostat, an HDAC inhibitor (epigenetics). Belinostat is already conditionally FDA-approved in the US as a 2nd line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo’s partner, Spectrum Pharmaceuticals, under the name Beleodaq® (belinostat IV form).
For further information, please visit www.onxeo.com.
Phone nb.: +33 1 45 58 76 00
Dušan Orešanský / Emmanuel Huynh
Investor Relations / Strategic Communications
Phone nb.: +33 1 44 71 94 92
Phone nb.: +33 1 44 71 94 98
Investor Relations US
Phone nb.: +1 212 915 2578
Er is ook een 2019 draadje maar toch een AB tje .
Direct naar Forum